Literature DB >> 20113905

Oral iron chelators.

Janet L Kwiatkowski1.   

Abstract

Effective chelation therapy can prevent or reverse organ toxicity related to iron overload, yet cardiac complications and premature death continue to occur, largely related to difficulties with compliance in patients who receive parenteral therapy. The use of oral chelators may be able to overcome these difficulties and improve patient outcomes. A chelator's efficacy at cardiac and liver iron removal and side-effect profile should be considered when tailoring individual chelation regimens. Broader options for chelation therapy, including possible combination therapy, should improve clinical efficacy and enhance patient care. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20113905     DOI: 10.1016/j.hoc.2009.11.001

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  8 in total

Review 1.  The exochelins of pathogenic mycobacteria: unique, highly potent, lipid- and water-soluble hexadentate iron chelators with multiple potential therapeutic uses.

Authors:  Lawrence D Horwitz; Marcus A Horwitz
Journal:  Antioxid Redox Signal       Date:  2014-06-20       Impact factor: 8.401

2.  Recent new drug approvals, part 2: drugs undergoing active clinical studies in children.

Authors:  Rebecca F Chhim; Chasity M Shelton; Michael L Christensen
Journal:  J Pediatr Pharmacol Ther       Date:  2013-01

3.  Synthesis and characterization of a triazine dendrimer that sequesters iron(III) using 12 desferrioxamine B groups.

Authors:  Jongdoo Lim; Vincent J Venditto; Eric E Simanek
Journal:  Bioorg Med Chem       Date:  2010-05-20       Impact factor: 3.641

4.  Altered zinc transport disrupts mitochondrial protein processing/import in fragile X-associated tremor/ataxia syndrome.

Authors:  Eleonora Napoli; Catherine Ross-Inta; Sarah Wong; Alicja Omanska-Klusek; Cedrick Barrow; Christine Iwahashi; Dolores Garcia-Arocena; Danielle Sakaguchi; Elizabeth Berry-Kravis; Randi Hagerman; Paul J Hagerman; Cecilia Giulivi
Journal:  Hum Mol Genet       Date:  2011-05-10       Impact factor: 6.150

5.  Iron overload during follow-up after tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma.

Authors:  Soo Jin Bae; Christine Kang; Ki Woong Sung; Hee Won Chueh; Meong Hi Son; Soo Hyun Lee; Keon Hee Yoo; Hong Hoe Koo
Journal:  J Korean Med Sci       Date:  2012-03-21       Impact factor: 2.153

Review 6.  Iron-induced fibrin in cardiovascular disease.

Authors:  Boguslaw Lipinski; Etheresia Pretorius
Journal:  Curr Neurovasc Res       Date:  2013-08       Impact factor: 1.990

Review 7.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

8.  Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior.

Authors:  Shahla Ansari; Azita Azarkeivan; Ghasem Miri-Aliabad; Saeed Yousefian; Tahereh Rostami
Journal:  Caspian J Intern Med       Date:  2017
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.